<DOC>
	<DOCNO>NCT00704106</DOCNO>
	<brief_summary>We propose largely retrospective study short-term prospective follow-up subgroup patient yet treat 48 week entecavir follow partial response adefovir . The aim study describe sequential virologic response adefovir entecavir .</brief_summary>
	<brief_title>Hepatitis B Virus ( HBV ) Viral Suppression Entecavir Adefovir Partial Responders</brief_title>
	<detailed_description>Amendment make , approve WIRB January 2009 , protocol : We propose largely retrospective study short-term prospective follow-up subgroup patient yet treat 96 week entecavir follow adefovir treatment . The aim study describe sequential virologic response adefovir entecavir .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Adefovir</mesh_term>
	<mesh_term>Adefovir dipivoxil</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<criteria>KEY INCLUSION CRITERIA : Age 18 year old All gender ethnicity Positive HBsAg HBeAg positive negative Pretreatment HBV DNA 10,000 copies/mL high ( purpose study , copy equivalent IU measurement record analyze ) Patients switch , prescribe , entecavir treatment adefovir least 12 week provide physician . Patients without prior lamivudine exposure enrol enrollment lamivudine experience case limit 30 patient total KEY EXCLUSION CRITERIA : Patients refuse consent study Patients young 18 Vulnerable subject pregnant woman , prisoner , employee , patient significant cognitive deficit . Patients prior exposure another nucleoside 2 week . Those prior exposure lamivudine enrol condition detail . HIV coinfection HCV coinfection HDV coinfection Recipients solid organ transplantation Patients receive highdose steroid ( 60 mg/d high long 10 day )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Hepatitis B</keyword>
	<keyword>HBV</keyword>
	<keyword>Treatment</keyword>
</DOC>